Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded to Buy at Wall Street Zen

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Sunday.

A number of other equities research analysts have also recently issued reports on the company. Wedbush restated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, April 16th. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Finally, Citigroup assumed coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of “Buy” and a consensus price target of $38.80.

Kiniksa Pharmaceuticals International Stock Up 1.5%

KNSA stock opened at $27.86 on Friday. The company has a market cap of $2.03 billion, a PE ratio of -111.42 and a beta of 0.05. Kiniksa Pharmaceuticals International has a 52 week low of $17.82 and a 52 week high of $30.69. The business has a 50-day simple moving average of $27.49 and a 200 day simple moving average of $22.90.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. The company had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same quarter last year, the firm posted ($0.25) EPS. The company’s quarterly revenue was up 72.5% on a year-over-year basis. On average, analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, CFO Mark Ragosa sold 21,254 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $26.95, for a total value of $572,795.30. Following the completion of the transaction, the chief financial officer owned 27,009 shares in the company, valued at approximately $727,892.55. The trade was a 44.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eben Tessari sold 45,042 shares of the firm’s stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the completion of the sale, the chief operating officer owned 72,363 shares of the company’s stock, valued at $2,207,795.13. This trade represents a 38.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 440,863 shares of company stock worth $12,101,029 over the last three months. 53.48% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KNSA. GAMMA Investing LLC lifted its stake in Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after acquiring an additional 568 shares during the period. US Bancorp DE acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth about $33,000. Asset Management One Co. Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth about $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth about $42,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth about $61,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.